The ACC’s Heart Failure and SGLT2is: The New Pillar in Care Initiative is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 …

SGLT2 inhibitors were added to heart failure guidelines in 2022. Dapagliflozin and empagliflozin have shown benefits in patients with HFrEF, HFpEF, and HFmrEF with or without diabetes.7 …

Jun 3, 2025 · SGLT2 inhibitors have become an important class of medication in managing heart failure. Initially developed to treat diabetes, these drugs have shown clear benefits for patients …

Mar 13, 2023 · Abstract Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (HF) with reduced ejection …

Mar 26, 2025 · SGLT2 Inhibitors in Heart Failure: New Evidence Changes Treatment Protocols Quick video summary of the detailed article below. Introduction Heart failureis a global health …

Jun 1, 2025 · Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are oral antidiabetic agents that have shown significant improvements in cardiovascular and renal outcomes …

Apr 26, 2023 · Abstract The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and …

ABSTRACT Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-di-rected medical therapy in heart failure (HF) with reduced ejection fraction with …

Start dapagliflozin or empagliflozin on the advice of a heart failure specialist. Dapagliflozin and empagliflozin are recommended as options for treating symptomatic chronic heart failure with …

Mar 17, 2023 · US Pharm. 2023;48 (3):45-48. ABSTRACT: Heart failure with preserved ejection fraction (HFpEF) is a chronic disease that is increasing in prevalence and contributes to the …